Immunoprecise Antibodies Ltd Market Cap ($95.54 Million)
Market Cap & Net Worth: Immunoprecise Antibodies Ltd (IPA)
Immunoprecise Antibodies Ltd market cap. Immunoprecise Antibodies Ltd (NASDAQ:IPA) has a market capitalization of $95.54 Million ($95.54 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19194 globally and #4432 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunoprecise Antibodies Ltd's stock price $2.07 by its total outstanding shares 46154100 (46.15 Million). Also see Immunoprecise Antibodies Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Immunoprecise Antibodies Ltd Market Cap History (2015–2025)
Immunoprecise Antibodies Ltd market cap history from 2015 to 2025. Data shows growth from $692.31K to $95.54 Million (20.99% CAGR). Check Immunoprecise Antibodies Ltd stock price for real-time trading data and today's change.
Index Memberships
Immunoprecise Antibodies Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #537 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1840 of 3165 |
Weight: Immunoprecise Antibodies Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immunoprecise Antibodies Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunoprecise Antibodies Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore IPA net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.90x
Immunoprecise Antibodies Ltd's market cap is 3.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $230.77K | $1.90 Million | $151.03K | 0.12x | 1.53x |
| 2017 | $107.77 Million | $2.63 Million | -$5.38 Million | 40.96x | N/A |
| 2018 | $117.92 Million | $5.44 Million | -$5.17 Million | 21.67x | N/A |
| 2019 | $101.54 Million | $10.93 Million | -$7.62 Million | 9.29x | N/A |
| 2020 | $690.00 Million | $14.06 Million | -$4.95 Million | 49.08x | N/A |
| 2021 | $247.39 Million | $17.91 Million | -$7.34 Million | 13.81x | N/A |
| 2022 | $240.46 Million | $19.36 Million | -$16.71 Million | 12.42x | N/A |
| 2023 | $78.92 Million | $20.66 Million | -$26.56 Million | 3.82x | N/A |
| 2024 | $19.00 Million | $24.52 Million | -$27.18 Million | 0.78x | N/A |
| 2025 | $95.54 Million | $24.52 Million | -$30.23 Million | 3.90x | N/A |
Competitor Companies of IPA by Market Capitalization
Companies near Immunoprecise Antibodies Ltd in the global market cap rankings as of November 5, 2026. Also see how large is Immunoprecise Antibodies Ltd's balance sheet for a full breakdown of the balance sheet.
Key companies related to Immunoprecise Antibodies Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Immunoprecise Antibodies Ltd (2015–2025)
Market capitalization of Immunoprecise Antibodies Ltd from 2015 to today. Between 2015 and today, Immunoprecise Antibodies Ltd's market cap moved from $692.31K to $ 95.54 Million, with a yearly change of 20.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $95.54 Million | +402.79% |
| 2024 | $19.00 Million | -75.92% |
| 2023 | $78.92 Million | -67.18% |
| 2022 | $240.46 Million | -2.80% |
| 2021 | $247.39 Million | -64.15% |
| 2020 | $690.00 Million | +579.55% |
| 2019 | $101.54 Million | -13.89% |
| 2018 | $117.92 Million | +9.42% |
| 2017 | $107.77 Million | +46600.00% |
| 2016 | $230.77K | -66.67% |
| 2015 | $692.31K | -- |
End of Day Market Cap According to Different Sources
On Sep 2nd, 2026 the market cap of Immunoprecise Antibodies Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $95.54 Million USD |
| MoneyControl | $95.54 Million USD |
| MarketWatch | $95.54 Million USD |
| marketcap.company | $95.54 Million USD |
| Reuters | $95.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immunoprecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in … Read more